CLAIM #11970 · Bristol-Myers Squibb Company (BMY) · 2024Q2 earnings call · Jul 26, 2024 · due Jan 31, 2025
“I would think about bolt-on deals and partnerships as being the priority for us in the immediate term.”
Chris Boerner · CEO
In context
“mber, and certainly, Adam can speak to that. As David also mentioned, I would highlight that we're also focused on paying down the debt as a top priority. Beyond that though, business development and partnerships are going to be continue -- continue to be important to us in terms of the types of deals that we're interested in. Obviously, they have to make strategic and financial sense as a first order. We're going to continue to be disciplined there. As I mentioned in my prepared remarks, you saw the therapeutic areas and modalities that we're focused on and where we feel we have a right to win. So those would be primarily the areas of focus for business development. And then the requisite question on obesity, I'll get to in a second, but there's also a requisite question on size of deal. I would think about bolt-on deals and partnerships as being the priority for us in the immediate term. And look, we're going to continue to monitor the obesity market, but I would say with respect to business development for us right now, I would focus on those areas that I highlighted in my prepared remarks. David? David Elkins: Chris, I think you covered it well. The only thing I'd emphasize as we think about capital allocation overall besides the debt paydown is we remain firmly committed to the dividend as evidenced by us paying a dividend for the past 92 years and increasing it the last 15 years. And as you know, we have one of the lowest payout ratios of our peer group. So overall, we remain very financially disciplined from a capital allocation perspective. Tim Power: Great. Thanks, David. Can we go to the next question, please, Rocco? Operator: Absolutely. Our next question today c”
Verify independently
SEC filings for BMY ↗ · Claim quote is verbatim from the 2024Q2 earnings call.